on Galenica AG (isin : CH0360674466)
Galenica records solid growth in 2024
In 2024, Galenica AG reported sales growth of 4.7% to CHF 3,922 million. This performance outpaces the Swiss pharmaceutical market growth of 3.5% according to IQVIA. The increase is attributed to strong momentum in the second half of the year, which saw a 6.7% increase driven by market share gains. Organic growth in pharmacies played a key role, although hampered by high generic sales and low influenza activity.
The "Products & Care" segment developed favourably, recording sales of CHF 1,700.2 million (+3.9%). The "Logistics & IT" segment also saw notable growth to CHF 3,240.7 million (+5.3%). Galenica confirms its outlook for the year, predicting an increase in EBIT of 8% to 11%.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Galenica AG news